Murphy K, Weaver C. Janeway’s Immunobiology. 9th edition. Garland Science.
Revised nomenclature for antigen-nonspecific T cell proliferation and helper factors. J Immunol. 1979;123:2928–9.
Nomenclature for secreted regulatory proteins of the immune system (interleukins). WHO-IUIS Nomenclature Subcommittee on Interleukin Designation. Bull World Health Organ. 1991;69:483–6.
Nomenclature for secreted regulatory proteins of the immune system (interleukins): update. IUIS/WHO Standing Committee on Interleukin Designation. Bull World Health Organ. 1997;75:175.
Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016;138:984–1010.
CAS PubMed Article Google Scholar
Brocker C, Thompson D, Matsumoto A, Nebert DW, Vasiliou V. Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum Genom. 2010;5:30–55.
Hymowitz SG, Filvaroff EH, Yin J, Lee J, Cai L, Risser P, et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J. 2001;20:5332–41.
CAS PubMed PubMed Central Article Google Scholar
Coondoo A. Cytokines in dermatology—a basic overview. Indian J Dermatol. 2011;56:368–74.
PubMed PubMed Central Article Google Scholar
Dinarello CA. Historical review of cytokines. Eur J Immunol. 2007;37:S34-45.
CAS PubMed PubMed Central Article Google Scholar
Jia H, Liu J, Han B. Reviews of interleukin-37: functions, receptors, and roles in diseases. BioMed Res Int. 2018;2018: e3058640.
Lin H, Ho AS, Haley-Vicente D, Zhang J, Bernal-Fussell J, Pace AM, et al. Cloning and characterization of IL-1HY2, a novel interleukin-1 family member*. J Biol Chem. 2001;276:20597–602.
CAS PubMed Article Google Scholar
Zenewicz LA, Flavell RA. Recent advances in IL-22 biology. Int Immunol. 2011;23:159–63.
CAS PubMed Article Google Scholar
Wynn TA. IL-13 effector functions. Annu Rev Immunol. 2003;21:425–56.
CAS PubMed Article Google Scholar
Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV. Interleukin 21: combination strategies for cancer therapy. Nat Rev Drug Discov. 2008;7:231–40.
CAS PubMed Article Google Scholar
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509.
CAS PubMed Article Google Scholar
Johnston A, Xing X, Wolterink L, Barnes DH, Yin Z, Reingold L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140:109–20.
CAS PubMed Article Google Scholar
Onoufriadis A, Simpson MA, Pink AE, Di Meglio P, Smith CH, Pullabhatla V, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89:432–7.
CAS PubMed PubMed Central Article Google Scholar
Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei X-Y, Fraitag S, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365:620–8.
CAS PubMed Article Google Scholar
Viguier M, Guigue P, Pagès C, Smahi A, Bachelez H. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann Intern Med. 2010;153:66–7.
Hüffmeier U, Wätzold M, Mohr J, Schön MP, Mössner R. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol. 2014;170:202–4.
Ganesan R, Raymond EL, Mennerich D, Woska JR, Caviness G, Grimaldi C, et al. Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies. MAbs. 2017;9:1143–54.
CAS PubMed PubMed Central Article Google Scholar
Tauber M, Viguier M, Le Gall C, Smahi A, Bachelez H. Is it relevant to use an interleukin-1-inhibiting strategy for the treatment of patients with deficiency of interleukin-36 receptor antagonist? Br J Dermatol. 2014;170:1198–9.
CAS PubMed Article Google Scholar
Bachelez H, Choon S-E, Marrakchi S, Burden AD, Tsai T-F, Morita A, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380:981–3.
EMA validates spesolimab marketing authorization application in GPP | Press [Internet]. boehringer-ingelheim.com [cited 2021 Nov 14]. https://www.boehringer-ingelheim.com/press-release/ema-filing-acceptance-and-validation-spesolimab.
Reich A, Barker J, Pink A, Reynolds NJ, Griffiths CEM, Kalapanda R, et al. Imsidolimab, an anti-IL-36 receptor monoclonal antibody, in the treatment of generalized pustular psoriasis: results from a phase 2 trial. 2021. p. 1–15.
Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, May LT, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. PNAS Natl Acad Sci. 1989;86:6367–71.
Palmou-Fontana N, Gaviño JAS, McGonagle D, García-Martinez E, Martín LIO. Tocilizumab-induced psoriasiform rash in rheumatoid arthritis. DRM. 2014;228:311–3.
Laurent S, Le Parc J-M, Clérici T, Bréban M, Mahé E. Onset of psoriasis following treatment with tocilizumab. Br J Dermatol. 2010;163:1364–5.
CAS PubMed Article Google Scholar
Wendling D, Letho-Gyselinck H, Guillot X, Prati C. Psoriasis onset with tocilizumab treatment for rheumatoid arthritis. J Rheumatol. 2012;39:657.
Fritz Y, Klenotic PA, Swindell WR, Yin ZQ, Groft SG, Zhang L, et al. Induction of alternative proinflammatory cytokines accounts for sustained psoriasiform skin inflammation in IL-17C+IL-6KO mice. J Invest Dermatol. 2017;137:696–705.
CAS PubMed Article Google Scholar
Blauvelt A. IL-6 differs from TNF-α: unpredicted clinical effects caused by IL-6 blockade in psoriasis. J Invest Dermatol. 2017;137:541–2.
CAS PubMed Article Google Scholar
Takematsu H, Tagami H. Quantification of chemotactic peptides (C5a anaphylatoxin and IL-8) in psoriatic lesional skin. Arch Dermatol. 1993;129:74–80.
CAS PubMed Article Google Scholar
Duan H, Koga T, Kohda F, Hara H, Urabe K, Furue M. Interleukin-8-positive neutrophils in psoriasis. J Dermatol Sci. 2001;26:119–24.
CAS PubMed Article Google Scholar
Trepicchio WL, Ozawa M, Walters IB, Kikuchi T, Gilleaudeau P, Bliss JL, et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest. 1999;104:1527–37.
CAS PubMed PubMed Central Article Google Scholar
Tonel G, Conrad C, Laggner U, Di Meglio P, Grys K, McClanahan TK, et al. Cutting edge: a critical functional role for IL-23 in psoriasis. J Immunol. 2010;185:5688–91.
CAS PubMed Article Google Scholar
Kulig P, Musiol S, Freiberger SN, Schreiner B, Gyülveszi G, Russo G, et al. IL-12 protects from psoriasiform skin inflammation. Nat Commun. 2016;7:13466.
CAS PubMed PubMed Central Article Google Scholar
Diels J, Thilakarathne P, Cameron C, McElligott S, Schubert A, Puig L. Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis. Br J Dermatol. 2020;183:276–84.
CAS PubMed PubMed Central Article Google Scholar
Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour J-P, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376:1551–60.
CAS PubMed Article Google Scholar
Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128:1207–11.
CAS PubMed Article Google Scholar
Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55:379–90.
CAS PubMed PubMed Central Article Google Scholar
Stritesky GL, Yeh N, Kaplan MH. IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol. 2008;181:5948–55.
CAS PubMed Article Google Scholar
Rizzo HL, Kagami S, Phillips KG, Kurtz SE, Jacques SL, Blauvelt A. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol. 2011;186:1495–502.
CAS PubMed Article Google Scholar
Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385:142–52.
CAS PubMed Article Google Scholar
Papp KA, Weinberg MA, Morris A, Reich K. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet. 2021;397:1564–75.
留言 (0)